Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Gilead Sciences, Inc. (NasdaqNM:GILD)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 27Price hit new 52-week high ($63.49)
Location
333 Lakeside Drive
Foster City, CA 94404
Phone: (650) 574-3000
Fax: (650) 578-9264
Email: corporate_communications@gilead.com
Employees (last reported count): 850
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Subsidiaries
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 400 MidCap
Ownership
·Insider and 5%+ Owners: 22%
·Over the last 6 months:
 · 11 insider sells; 179.0K shares
  (0.8% of insider shares)
·Institutional: 86% (110% of float)
(508 institutions)
·Net Inst. Buying: 7.05M shares (+7.94%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. The Company discovers, develops, manufactures and commercializes proprietary therapeutics for challenging infectious diseases (viral, fungal and bacterial infections) and cancer. Gilead also has expertise in liposomal drug delivery technology. Currently, the Company markets AmBisome ((amphotericin B) liposome for injection), an antifungal agent, DaunoXome (daunorubicin citrate liposome injection), a drug approved for the treatment of Kaposi's Sarcoma, and VISTIDE (cidofovir injection) for the treatment of cytomegalovirus (CMV) retinitis. Hoffmann-La Roche, Inc. markets Tamiflu (oseltamivir phosphate) for the treatment of influenza, under a collaborative agreement with Gilead. In addition, Gilead is developing products to treat diseases caused by human immunodeficiency virus and hepatitis B virus, bacterial infections and cancer.
More from Market Guide: Expanded Business Description

Financial Summary
Gilead Sciences, Inc. provide accelerated solutions for patients and caretakers with a focus on developing and marketing drugs to treat patients with infectious diseases. For the six months ended 6/30/01, revenues rose 11% to $108.5 million. Net loss before accounting change totaled $55.2 million, up from $7.3 million. Revenues reflect increased product sales. Earnings were offset by an up-front license fee paid to Cubist for the daptomycin licensing agreement.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

James Denny, 68
Chairman
--  --  
John Martin, Ph.D., 49
Pres, CEO, Director
$534K$4.1M
Sharon Surrey-Barbari, 46
CFO, VP
--  --  
Norbert Bischofberger, Ph.D., 45
Exec. VP of R&D
365K2.3M
Mark Perry, 45
Exec. VP, Operations
350K4.1M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GILDAs of 31-Aug-2001
Price and Volume
52-Week Low
on 8-Jan-2001
$24.875
Recent Price$60.71 
52-Week High
on 27-Aug-2001
$63.49 
Beta1.38 
Daily Volume (3-month avg)1.65M
Daily Volume (10-day avg)1.84M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+15.6%
52-Week Change
relative to S&P500
+55.1%
Share-Related Items
Market Capitalization$5.78B
Shares Outstanding95.2M
Float74.3M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 22-Feb-2001
Per-Share Data
Book Value (mrq)$3.30 
Earnings (ttm)-$0.97 
Earnings (mrq)-$0.34 
Sales (ttm)$2.21 
Cash (mrq)$4.79 
Valuation Ratios
Price/Book (mrq)18.38 
Price/EarningsN/A 
Price/Sales (ttm)27.48 
Income Statements
Sales (ttm)$206.2M
EBITDA (ttm)-$88.0M
Income available to common (ttm)-$91.0M
Profitability
Profit Margin (ttm)-42.7%
Operating Margin (ttm)-49.4%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-15.49%
Return on Equity (ttm)-27.11%
Financial Strength
Current Ratio (mrq)9.63 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$456.0M
Short Interest
As of 8-Aug-2001
Shares Short4.71M
Percent of Float6.3%
Shares Short
(Prior Month)
4.98M
Short Ratio3.29 
Daily Volume1.43M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.